bioAffinity Technologies Announces $1.8M Direct Offering

An announcement from bioAffinity Technologies, Inc. ( (BIAF) ) is now available.

On October 8, 2025, bioAffinity Technologies, Inc. announced a securities purchase agreement with institutional investors for a registered direct offering of 720,000 shares of common stock, which closed on October 9, 2025, raising approximately $1.8 million. The proceeds are intended to support working capital, growing sales for CyPath® Lung, and general corporate purposes, with WallachBeth Capital, LLC acting as the sole placement agent. The company has agreed to certain restrictions on issuing additional shares and entering variable rate transactions until specified dates, impacting their operational flexibility and market strategy.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Underperform.

The overall stock score is primarily driven by the company’s weak financial performance and bearish technical indicators. The negative P/E ratio and lack of dividend yield further contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive tests for early-stage cancer detection and broad-spectrum cancer treatments. Their first product, CyPath® Lung, is a noninvasive test marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.

Average Trading Volume: 2,412,769

Technical Sentiment Signal: Sell

Current Market Cap: $4.54M

For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.